Targeted inhibition of PD‐1/PD‐L1 and other family members is emergingly regarded as a novel STCs‐eliminating strategy, with clinical value identified across multiple tumor types including melanoma, NSCLC, renal cell carcinoma, and bladder cancer [548]. This evidence concerns the gene CD274 and neoplasm.